Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your experience. Save up to 40% More details

Teva Pharm Q3 profit misses estimates, sees recovery into Q4

Stock MarketsOct 27, 2021 11:06AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
© Reuters. FILE PHOTO: The logo of Teva Pharmaceutical Industries is seen in Tel Aviv, Israel February 19, 2019. REUTERS/Amir Cohen/File Photo

By Steven Scheer

JERUSALEM (Reuters) -Israel-based Teva Pharmaceutical Industries (NYSE:TEVA) reported third-quarter profit that missed estimates, citing lower North American sales but said a post-COVID recovery would allow it to meet its 2021 targets.

The company trimmed its revenue outlook in July due to a slower bounceback from the pandemic but now sees its business nearly close to pre-pandemic levels.

"We have good reason to believe that because we are not seeing any new lockdowns in Europe ... and in the U.S.," Chief Executive Officer Kare Schultz told a conference call. On prescriptions, "we're getting very close to the 2019 levels."

Teva reaffirmed its 2021 forecasts of adjusted EPS of $2.50-$2.70 and revenue of $16.0-$16.4 billion, compared with adjusted EPS of $2.57 and revenue of $16.7 billion in 2020.

In the third quarter, the world's largest generic drugmaker said it earned 59 cents per diluted share excluding one-time items in the July-September period, up from 58 cents a share a year earlier. Revenue fell 2% to $3.89 billion.

Analysts had forecast Teva would earn 65 cents a share ex-items on revenue of $4.03 billion, according to I/B/E/S data from Refinitiv.

Teva's New York listed shares were down 3.9% at $9.02 in morning trading.

After a slow start to the year, Huntington's disease treatment Austedo and migraine product Ajovy continue to show revenue gains, growing 19% and 31% respectively in the United States in the quarter. Teva expects sales of Austedo to reach $850 million and Ajovy $300 million this year, with Schultz reiterating an expectation of Ajovy ultimately reaching a one-third market share, from 21% in the U.S. currently.

Sales in North America fell to $1.88 billion the quarter from $2.02 billion a year earlier. Overall generic drug sales in North America slipped 7% to $859 million, while sales in Europe grew 9% to $1.22 billion.

Its former blockbuster multiple sclerosis drug Copaxone showed another U.S. sales drop of 44% amid strong generic competition.

Teva paid down another $1 billion in the quarter, bringing its net debt to $21.7 billion. While the company has targeted a net debt to EBITDA level of three times by 2023, Schultz told Reuters the company would likely be aggressive until around 2025 when debt should fall to a more manageable $10-$12 billion.

With debt high, Schultz said Teva was in no position to make any more acquisitions. He told Reuters Teva was not interested in buying Sandoz from Novartis for financial reasons and a high overlap in their biosimilars portfolios. Novartis this week raised the prospect of divesting its generic drugs unit Sandoz as price pressures mount.

On the ongoing opioid lawsuits in the United States, Schultz said Teva remained in talks with state attorney generals and was hopeful for a settlement within 12 months. He said the upcoming New York trial could serve as a trigger for a settlement.

The company also said it was selling $4 billion of sustainability-linked senior notes to refinance its debt and to secure access to medicines in low and middle-income countries.

Teva Pharm Q3 profit misses estimates, sees recovery into Q4

Related Articles

More Chinese developers seek domestic bond issuance
More Chinese developers seek domestic bond issuance By Reuters - Dec 01, 2021

SHANGHAI (Reuters) - Three Chinese developers, including the main operation platforms of Country Garden Holdings Co and Longfor Group Holdings Ltd, plan to sell bonds in China to...

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at’s discretion.

Write your thoughts here
Are you sure you want to delete this chart?
Post also to:
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Are you sure you want to delete this chart?
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
Sign up with Email